Related Experiment Video
Updated: Aug 19, 2026

Efficient Method for Imaging Murine Lungs that Preserves Spatial Dynamics of Fungal Spores in the Airways
Published on: December 13, 2024
Central Nervous System Coccidioides immitis Infections
1Neurology Service, New Mexico VA Health Care System, 1501 San Pedro Drive SE, Albuquerque, NM 87108, USA. LEDavis@unm.edu.
Abstract:
Coccidioidal meningitis occurs in healthy individuals and patients with AIDS or other immunosuppressive illnesses. The central nervous system infection results when Coccidioides immitis disseminates from a primary lung infection via a fungemia to reach the meninges. Cases develop primarily in individuals living in or traveling to the Lower Sonoran Life Zone of Southwest United States. Most cases begin as subacute granulomatous meningitis with occasional patients developing brain abscesses. Diagnosis may be challenging because C. immitis is isolated from cerebrospinal fluid in less than 50% of patients. However, a cerebrospinal fluid complement fixation test for IgG antibody to C. immitis has high sensitivity and specificity. Currently, optimal treatment is unclear. Standard therapy has been with life-long oral fluconazole or intrathecal amphotericin B followed by prolonged oral fluconazole. Liposomal amphotericin B given intravenously seems promising as an initial treatment as it has much higher brain penetration, less nephrotoxicity, and less severe infusion-related adverse effects than conventional amphotericin B. However, current comparative studies for efficacy of liposomal amphotericin B in coccidioidal meningitis are lacking.
Insights
Coccidioidal meningitis, a fungal infection of the brain, affects immunocompromised individuals. While diagnosis can be difficult, antibody tests are effective, and new treatments like liposomal amphotericin B show promise.
Area of Science:
- Mycology
- Infectious Diseases
- Neurology
Background:
- Coccidioidal meningitis is a serious central nervous system infection caused by the fungus Coccidioides immitis.
- It often arises from a primary lung infection and disseminates to the meninges, particularly in endemic areas like the Lower Sonoran Life Zone.
- The condition can affect both healthy individuals and those with compromised immune systems, including patients with AIDS.
Purpose of the Study:
- To review the epidemiology, diagnosis, and treatment of coccidioidal meningitis.
- To highlight diagnostic challenges and the utility of serological tests.
- To discuss current and potential therapeutic strategies, including novel antifungal agents.
Main Methods:
- Literature review of coccidioidal meningitis cases and treatment outcomes.
- Analysis of diagnostic methods, focusing on cerebrospinal fluid analysis and serological testing.
- Evaluation of current and investigational treatment regimens, including oral and intravenous antifungal therapies.
Main Results:
- Coccidioidal meningitis diagnosis is often challenging, with C. immitis isolated from cerebrospinal fluid in less than 50% of cases.
- A cerebrospinal fluid complement fixation test for IgG antibody to C. immitis demonstrates high sensitivity and specificity for diagnosis.
- Optimal treatment remains unclear, with standard therapies including fluconazole or amphotericin B, while liposomal amphotericin B shows potential due to improved properties.
Conclusions:
- Coccidioidal meningitis requires prompt diagnosis and management, often necessitating long-term antifungal therapy.
- While diagnostic tools like antibody testing are valuable, further comparative studies are needed to establish the optimal treatment regimen.
- Liposomal amphotericin B presents a promising alternative for initial treatment due to its favorable pharmacokinetic and safety profile compared to conventional amphotericin B.
Related Concept Videos
Cryptococcal Meningitis
Fungal Phylum Microsporidia
American Trypanosomiasis
Cytomegalovirus Disease
Leishmaniasis
Candidiasis